DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
“Microdosing” means taking a dose of semaglutide or tirzepatide below any amount the FDA studied. It is trending in 2026 — but there are no randomized trials behind it, and obesity-medicine clinicians call it experimental and unsupported. Here is what people actually do, what the (weak) evidence shows, and the big unknowns.
“Microdosing” a GLP-1 means deliberately taking a dose lower than any the FDA approved — often below even the 4-week starter dose. Crucially, there is no single definition. As STAT News put it in 2026, there “isn’t even a single definition of microdosing for weight loss or any other condition.” [1] The word was popularized by direct-to-consumer telehealth and compounding sellers — not by researchers — so two people who say they are “microdosing” may be taking very different amounts of very different products.
In practice it almost always involves compounded semaglutide or tirzepatide drawn from a multi-dose vial, because branded pens deliver fixed, labeled doses. That detail matters for the risks below.
GLP-1s commonly cause nausea, vomiting, and diarrhea, especially early on. People who struggle with these hope a smaller dose keeps some appetite effect with fewer GI side effects. UCLA Health notes the goal people describe is “to curb hunger just enough to make a weight-loss regimen easier to sustain.” [4]
A vial used in smaller amounts lasts longer, so the monthly spend drops. STAT notes the appeal is “a little extra GLP-1 in their bodies, at a low price,” [1] and reports that telehealth firms have leaned into microdosing as a way to extend the compounding market. [2]
Both goals are reasonable. The problem is the leap from “I want fewer side effects / lower cost” to “a sub-therapeutic dose delivers the benefit safely” — that leap has not been tested.
This is the part the marketing skips. There are no randomized controlled trials showing that microdosed GLP-1s produce meaningful weight loss. The clinicians quoted in the coverage are consistent:
The deeper issue is dose-response. Every pivotal semaglutide and tirzepatide trial titrates patients up to specific maintenance doses, and benefit tracks with reaching those doses. That is why the labels have dose ladders at all — and why a dose below the studied floor has no efficacy data behind it. You may see big weight-loss numbers cited by sellers (for example, percentages from uncontrolled “real-world” cohorts); treat those as marketing, not evidence — they are not randomized, not blinded, and not comparable to the trials that earned these drugs their approvals.
The left column is the real, FDA-studied titration ladder from the prescribing labels. The right column is the sub-therapeutic range people and sellers describe online — there is no standard definition, and none of it has been studied. This chart exists to show the gap, not to suggest a dose.
| Medication | FDA-studied weekly doses (mg) | “Microdose” range people report (mg) — NOT studied |
|---|---|---|
| Semaglutide (Wegovy) | 0.25 → 0.5 → 1 → 1.7 → 2.4 (→ 7.2)Studied floor: 0.25 mg/wk (4-week starter only) | ~0.05–0.25 mg/wkBelow any studied dose |
| Tirzepatide (Zepbound) | 2.5 → 5 → 7.5 → 10 → 12.5 → 15Studied floor: 2.5 mg/wk (4-week starter only) | ~0.5–2.5 mg/wkBelow any studied dose |
This is a reference, not a recommendation. The right-hand ranges are doses people and telehealth sellers describe online— there is no standard definition of a “microdose,” and none of these sub-therapeutic ranges have been studied for safety or efficacy. The FDA starter doses (0.25 mg semaglutide, 2.5 mg tirzepatide) are titration steps, not maintenance doses, and trials show benefit only at higher doses. Never set or change a dose without a clinician.
Microdosing is an unstudied, off-label practice. Because it is not measured, the honest position is that the key questions are simply unanswered:
None of this is dosing advice. It is a map of the unknowns so you can have an informed conversation with a clinician.
We are not going to tell you to microdose or not to — that is between you and a licensed prescriber who knows your history. But the framing we would use is simple: be clear about the problem you are actually trying to solve, then pick the path with real evidence behind it.
Editorial summary, not medical advice and not a recommendation to microdose. GLP-1 microdosing is off-label and has not been studied in controlled trials; compounded products are not FDA-approved. Dose ranges shown are what people and sellers report, not guidance. Always discuss any dosing decision with a licensed prescriber.